Enliven Therapeutics, Inc.
ELVN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $81 | $65 | $31 | $20 |
| G&A Expenses | $24 | $19 | $8 | $4 |
| SG&A Expenses | $24 | $19 | $8 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $105 | $84 | $39 | $25 |
| Operating Income | -$105 | -$84 | -$39 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $16 | $12 | $1 | $0 |
| Pre-Tax Income | -$89 | -$72 | -$38 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$89 | -$72 | -$38 | -$25 |
| % Margin | – | – | – | – |
| EPS | -1.89 | -2.01 | -6.03 | -3.17 |
| % Growth | 6% | 66.7% | -90.2% | – |
| EPS Diluted | -1.89 | -2.01 | -6.03 | -3.17 |
| Weighted Avg Shares Out | 47 | 36 | 6 | 8 |
| Weighted Avg Shares Out Dil | 47 | 36 | 6 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $12 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$104 | -$83 | -$39 | -$25 |
| % Margin | – | – | – | – |